Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)J. Jean Cui, Martin P. Edwards, Michelle Tran‐Dubé et al.|Journal of Medicinal Chemistry|2011Cited by 924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsTed W. Johnson, Martin P. Edwards, Paul Richardson et al.|Journal of Medicinal Chemistry|2014Cited by 587
Using the Golden Triangle to optimize clearance and oral absorptionTed W. Johnson, Martin P. Edwards, Klaus Dress|Bioorganic & Medicinal Chemistry Letters|2009Cited by 382
Lipophilic Efficiency as an Important Metric in Drug DesignTed W. Johnson, Martin P. Edwards, Rebecca A. Gallego|Journal of Medicinal Chemistry|2018Cited by 340
Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysisThomas Ryckmans, Tim Young, Martin P. Edwards et al.|Bioorganic & Medicinal Chemistry Letters|2009Cited by 269